Strong startup delegation at Medica 2024 (startupticker.ch)

Swiss ingenuity shines on TIME's Best Inventions 2024 list (startupticker.ch)

Boardroom powerhouses of industry veterans propel startups toward growth (startupticker.ch)

Innosuisse funds 33 projects as part of the Swiss Accelerator (startupticker.ch)

Tia joins Aspivix global ambassador program (startupticker.ch)

Swiss health care startups explore the UK market (startupticker.ch)

FIT Funding for Aspivix and Xemperia (startupticker.ch)

Bayer to accelerate adoption of Aspivix’s medical device (startupticker.ch)

Bayer (Schweiz) and ASPIVIX collaborate to reduce pain in Women’s Health procedures (venturelab.swiss)

Aiming for faster growth with new Board members (startupticker.ch)

CE Mark approval paves the way for Aspivix global commercialisation (startupticker.ch)

First National Flagship Event 2023: Credit Suisse Investors and TOP 100 Startups connect over archery in Lausanne (venturelab.swiss)

Positive results from Aspivix’s ADVANCE Women study (startupticker.ch)

US Sale of ASPIVIX Carevix greenlighted (startupticker.ch)

USD 5 million to speed ASPIVIX entry on European and US Markets (startupticker.ch)

ASPIVIX closes Series A+ funding round with USD 5 million and wins EUREKA-EUROSTARS grant (venturelab.swiss)

Aspivix sets its sights on Europe and the US (startupticker.ch)

Time Best Invention 2024

Aspivix featured in the New York times

ASPIVIX and Bayer Switzerland Collaborate to Reduce Pain in Women’s Health Procedures Including IUDs

ASPIVIX starts the Ambassador program in 12 EU and US hospitals and clinics to collect Real World Evidence with carevix and target 1000 procedures

CE Marking under new Medical Device Regulation for Carevix

Winner med-tech innovation award 2023

Randomized control trial published in Contraception Journal

510(k) - FDA Clearance for US market

IF DESIGN AWARD 2022 (Category Medecine/Health)

Extension of ISO 13485 Certification already granted in 2020 to include sterile products

We are thrilled to announce the enrollment completion of the Advance Women Clinical Trial, a First in Women study comparing patient pain in #IUD insertion using Aspivix novel device vs. the standard of care.

Aspivix's story - the movie

It was published today in Frontiers OBGYN the results of Aspivix ADVANCE WOMEN Clinical Trial - Pilot Phase conducted at the CHUV | Lausanne university hospital

Aspivix will be presenting a scientific poster at the 29th World Congress on Controversies in Obstetrics, Gynecology & Infertility @COGI Congress taking place in Berlin from December 2 – 4, 2021

Aspivix is delighted to announce a poster presentation of its First in Women Clinical Trial, at the 14th Congress of ESG - European Society of Gynecology taking place in Venice, November 10th to 13th, 2021.

Aspivix team members Andrea Albornoz and Mathieu Horras selected among the trailblazers disrupting the field of #FemTech.

ASPIVIX received 510(k) Clearance from U.S. Food and Drug Administration (FDA) for Aspivix Cervical Suction Stabilizer- our first-generation device.

Aspivix First in Women Phase-I trial was accepted for a poster presentation at the upcoming Swiss Annual Congress of Gynecology

Aspivix just completed a quantitative study with 152 gynecologists to map out the IUD Insertion Procedures in the US

1000 Followers on LinkedIN

ASPIVIX is proud to announce the start of its Phase II First-in-Women trial at the CHUV | Lausanne university hospital and HUG - Hôpitaux in Switzerland.

ASPIVIX will be joining the first Swiss #FemTech acceleration Program Tech4Eva dedicated to supporting disruptive start-ups to advance women’s health

1st Patent application granted, 2nd Patent application published

Authorization to start clinical trial from Ethical Committe and Swissmedic

Grant 2nd Phase Innosuisse Scale-up Programm

ISO 13485:2016 certification

Innosuisse Grant Certificate

Horizon2020 SME Instrument phase 2

Aspivix wins CHF 130,000

Passed Venture Kick stage 2

Won Startup Champions Seed Night 2018

Passed Horizon2020 SME Instrument phase 1

Venture Leaders life science Boston

Passed Venture Kick stage 1